FA
ACHL

Forefront Analytics’s Achilles Therapeutics ACHL Stock Holding History

Forefront Analytics’s Portfolio ACHL Stock Details ACHL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-95,445
Closed -$119K – 72
2024
Q1 		$119K Buy
95,445
+19,176
+25% +$20.7K 0.06% 58
2023
Q4 		$67.8K Sell
76,269
-1,900
-2% -$1.63K 0.03% 64
2023
Q3 		$71.1K Buy
78,169
+3,400
+5% +$3.23K 0.04% 59
2023
Q2 		$70.7K Sell
74,769
-856
-1% -$813 0.04% 60
2023
Q1 		$72.4K Buy
75,625
+45,100
+148% +$48.9K 0.04% 65
2022
Q4 		$27.5K Sell
30,525
-1,675
-5% -$2.82K 0.01% 73
2022
Q3 		$72K Buy
+32,200
New +$91.1K 0.04% 56

Other funds holding ACHL

SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
FIS
FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return

Forefront Analytics's ACHL Position: Q2 2024 in Review

Forefront Analytics sold out of Achilles Therapeutics (ACHL) in Q2 2024, closing a stake of 95,445 shares — an estimated $119K sold.

Forefront Analytics first reported a position in ACHL in Q3 2022 and held it in 7 quarters. The position peaked at $119K in Q1 2024. 27 funds tracked by Wall St. Rank hold ACHL as of Q2 2024.

  • Forefront Analytics reported no remaining Achilles Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Forefront Analytics sold 95,445 Achilles Therapeutics shares in Q2 2024, an estimated $119K.
  • Forefront Analytics first reported a position in Achilles Therapeutics in Q3 2022 and held it in 7 quarters.
  • Forefront Analytics's Achilles Therapeutics position peaked at $119K in Q1 2024.
  • 27 funds tracked by Wall St. Rank held Achilles Therapeutics as of Q2 2024.

Based on Forefront Analytics's 13F filing for Q2 2024, filed 15 Aug 2024.